AstraZeneca (www.astrazeneca.com) has become the first partner for BioWisdom’s (www.biowisdom.com) Safety Intelligence Program (SIP). Under the three-year agreement, AstraZeneca also joins the board. SIP delivers an intelligence system to support drug safety risk assessment at early stages of the discovery process, explains Julie Barnes, Ph.D., CSO at BioWisdom.
